Cruzado, Josep MLauzurica, RicardoPascual, JulioMarcen, RobertoMoreso, FrancescGutierrez-Dalmau, AlexAndrés, AmadoHernández, DomingoTorres, ArmandoBeneyto, Maria IsabelMelilli, EdoardoManonelles, AnnaArias, ManuelPraga, Manuel2025-01-072025-01-072017-09-28https://hdl.handle.net/10668/25186Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial. Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium 110 pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft protocol biopsies. The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the CAL group (P = 0.07). However, there was a higher percentage of patients with iPTH  Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/hyperparathyroidismkidney transplantationparicalcitolvitamin Dresearch article29340322open access10.1016/j.ekir.2017.08.0162468-0249PMC5762965http://www.kireports.org/article/S2468024917303741/pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5762965/pdf